Merck JV Ties Up With MEND To Focus On First Heat-stable Rotavirus Vaccine For Developing Markets
This article was originally published in PharmAsia News
MUMBAI - Hilleman Laboratories - the nonprofit joint venture between Merck & Co. and Wellcome Trust to develop affordable vaccines for low-income countries - has set its sights on developing a heat-stable form of rotavirus vaccine as its first project
You may also be interested in...
The vaccines research JV between Merck and Wellcome Trust has undergone major changes in its operations. The new plan is dramatically different from the one envisioned at the launch of the JV and narrows down on fewer disease areas with a predominant presence in enteric illnesses.
Four years after it established its first India base, U.S. FDA has effected a leadership change. The new chief is expected to play a double role as both guide and vigilant examiner.
MSD India Managing Director K.G. Ananthakrishnan On Disease Management And Taking A Holistic Approach: An Interview With PharmAsia News (Part 2 of 2)
Merck Sharp & Dohme India Managing Director K.G. Ananthakrishnan discusses MSD’s holistic approach to patient care in India, including disease management, physician education and responsible pricing.